Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-07 16:58 |
2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, SEPTEMBER …
|
English | 189.9 KB | ||
| 2023-08-07 15:59 |
Second Quarter 2023 Results
|
English | 266.5 KB | ||
| 2023-08-07 15:59 |
Second Quarter 2023 Results
|
English | 36.2 KB | ||
| 2023-07-24 15:59 |
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
|
English | 82.5 KB | ||
| 2023-07-24 15:59 |
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
|
English | 36.0 KB | ||
| 2023-07-17 15:59 |
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Pa…
|
English | 97.8 KB | ||
| 2023-07-17 15:59 |
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Pa…
|
English | 36.0 KB | ||
| 2023-06-24 01:14 |
Amendment No. 2 to FORM F-3
|
English | 81.1 KB | ||
| 2023-06-24 01:14 |
Amendment No. 2 to FORM F-3
|
English | 35.9 KB | ||
| 2023-06-22 15:59 |
First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizu…
|
English | 75.2 KB | ||
| 2023-06-22 15:59 |
First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizu…
|
English | 36.1 KB | ||
| 2023-06-13 15:59 |
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
English | 71.1 KB | ||
| 2023-06-13 15:59 |
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
English | 36.0 KB | ||
| 2023-06-05 15:59 |
Compugen’s COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Acti…
|
English | 80.0 KB | ||
| 2023-06-05 15:59 |
Compugen’s COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Acti…
|
English | 36.1 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
